- Home
- TCI vs KOD Comparison
TCI vs KOD Comparison
Compare TCI & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCI
- KOD
- Stock Information
- Founded
- TCI 1983
- KOD 2009
- Country
- TCI United States
- KOD United States
- Employees
- TCI N/A
- KOD N/A
- Industry
- TCI Real Estate
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TCI Finance
- KOD Health Care
- Exchange
- TCI Nasdaq
- KOD Nasdaq
- Market Cap
- TCI 239.1M
- KOD 198.4M
- IPO Year
- TCI N/A
- KOD 2018
- Fundamental
- Price
- TCI $43.27
- KOD $5.17
- Analyst Decision
- TCI
- KOD Hold
- Analyst Count
- TCI 0
- KOD 3
- Target Price
- TCI N/A
- KOD $9.00
- AVG Volume (30 Days)
- TCI 6.9K
- KOD 312.0K
- Earning Date
- TCI 08-07-2025
- KOD 08-13-2025
- Dividend Yield
- TCI N/A
- KOD N/A
- EPS Growth
- TCI 59.61
- KOD N/A
- EPS
- TCI 0.92
- KOD N/A
- Revenue
- TCI $47,452,000.00
- KOD N/A
- Revenue This Year
- TCI N/A
- KOD N/A
- Revenue Next Year
- TCI N/A
- KOD N/A
- P/E Ratio
- TCI $47.13
- KOD N/A
- Revenue Growth
- TCI N/A
- KOD N/A
- 52 Week Low
- TCI $25.50
- KOD $1.92
- 52 Week High
- TCI $46.74
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- TCI 55.51
- KOD 74.91
- Support Level
- TCI $43.26
- KOD $3.70
- Resistance Level
- TCI $46.23
- KOD $4.01
- Average True Range (ATR)
- TCI 1.35
- KOD 0.29
- MACD
- TCI -0.42
- KOD 0.13
- Stochastic Oscillator
- TCI 15.98
- KOD 98.18
About TCI Transcontinental Realty Investors Inc.
Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates multifamily and commercial properties throughout the southern United States and also invests in mortgage notes receivable and in the land that is either held for appreciation or development. The company has two business segments: the acquisition, development, ownership, and management of multifamily properties which include the rental of apartments (Residential Segment) and other tenant services, including parking and storage space rental, and the acquisition, development, ownership, and management of commercial properties which are office properties(Commercial Segment). It includes the rental of office space and other tenant services, including parking and storage space rental.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.